Targeting the host immune system to fight back against cancer has seen recent breakthroughs. The protein Heme Oxygenase-1 (HO-1) has recently been shown to suppress the immune system in breast cancer and that inhibiting HO-1 had therapeutic benefit. In this project, we will show that HO-1 is important in osteosarcoma and that inhibiting HO-1 with already-approved drugs can block osteosarcoma development and metastasis.

Project summary
Osteosarcoma is a devastating malignancy that affects patients of all ages. Chemotherapy and limb-sparing surgery has improved over the past years, however, the 5-year survival rate has not changed in nearly 30 years. This is because one of the most difficult complications is cancer spread and metastasis, and in the case of osteosarcoma, this is mainly to the lungs. There are great efforts made to understand the genetic basis of osteosarcoma and metastasis, but there are still many unanswered questions about what signals are present in the tumours that are driving cells to leave the primary tumour and metastasise to the lungs.
One of the current breakthroughs in the cancer field is in understanding how the immune system can be boosted to help fight back against the cancer. This is important because the standard chemotherapy treatment suppresses the immune system, allowing the cancer to escape attack from immune cells.
There has been intensive research into special cells called macrophages, normally present in all of us, which are important for our normal development. In cancer, macrophages are hijacked and altered by the cancer cells. Once hijacked, these cells are called Tumour Associated Macrophages (TAMs). It is these TAMs that are largely responsible for allowing cancer cells to evade attack by the host immune system, and these TAMs are generally present in all tumours, including in osteosarcoma. Therefore, in order to “kick-start” the body’s own defence system, these TAMs need to be targeted.
Professor Grigoriadis was encouraged by recent work conducted by a collaborator (Professor James Arnold) at Kings College London, who recently demonstrated that TAMs in breast cancer make factors called Fibroblast Activation Protein (FAP) and Heme Oxygenase-1 (HO-1), and that HO-1 can promote the growth of tumours by blocking the immune system. Therefore, it would be of great benefit to block HO-1. Fortunately, there are already drugs being used against HO-1. HO-1 is important in neonatal jaundice, and a drug called SnMP is used routinely to treat this. A breakthrough published recently shows that in pre-clinical models, treatment with SnMP was more effective at reducing tumour growth when compared to chemotherapy alone. This is very exciting and suggests there is scope for human cancer treatment.
Encouraged by this data, Professor Grigoriadis and his team established a collaboration with Professor Arnold to see if a similar mechanism might be operating in osteosarcoma. Preliminary experiments suggested that osteosarcoma also expresses high levels of FAP and HO-1. This prompted Professor Grigoriadis and his team to propose a simple initial study to confirm if these proteins are functional in osteosarcoma, and if the SnMP drug, either with or without chemotherapy, will reduce osteosarcoma growth and metastasis.
The research proposed in this Explorer grant aimed to focus on cells within osteosarcoma tumours, that are not tumour cells, rather, cells in the surrounding tumour environment (called the tumour microenvironment-TME).The TME is present in almost all cancers and is shown to regulate the growth of tumour cells and to be responsible for immune suppression and chemoresistance.The TME in OS is poorly understood, and our research aimed to investigate a particular group of cells in the TME called macrophages, that express an enzyme (HO-1) that is a promising therapeutic target in other cancers.
Results of the study:
Using a pre-clinical model of OS generated in the laboratory, we have shown for the first time that this new target, HO-1, is indeed present in developing bone tumours, interestingly, from its earliest stages of development, and continues to be expressed in mature tumours. Using a known drug (SnMP) that blocks HO-1 activity, we also showed that SnMP can reduce the ability of OS cells to metastasise to the lungs. Although preliminary, these results, together with ongoing research have very promising implications for bone cancer patients. Metastatic disease is the single most important prognostic factor in OS, as patient survival is still poor despite advances in chemotherapy and limb-salvage surgery. Their results are showing that, independently of the primary tumour, that targeting this HO-1 pathway that is present in the TME of bone tumours might provide a novel therapeutic protocol, in combination with chemotherapy, that can increase patient survival.
Future steps:
The research enabled by this Explorer grant has yielded new information that has enabled application for further funding that use complementary approaches to addressing how cells in the TME. The team continue to focus on two key events that are relevant to OS patients, how the primary tumour grows and expands within bone, and how OS cells colonise and grow in the lungs. Both processes appear to involve the macrophage-HO-1 axis and the fact that there exist potential therapeutics that can be used in combination with standard chemotherapy provides very exciting directions for future research.
The Bone Cancer Research Trust would like to thank the Clive and Sylvia Richards Charity for helping to make this project a reality.